Website Header with Language Selector and Dropdowns
Image

Cortexolone 17-Acetate


Catalog Number: CL-CTXL-08
CAS No.: 19357-45-0
Mol.F: C23H32O5
Mol.W: 388.5
Inv. Status: Custom Synthesis

Chemical Name: (8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate.

Country of Origin: India

Product Category: Cortexolone Impurities


Cortexolone 17-Acetate is identified by CAS No. 19357-45-0 and is chemically known as (8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate.

Cortexolone 17-Acetate is provided with comprehensive characterization data in accordance with regulatory guidelines. It is suitable for use in analytical method development, method validation (AMV), Quality Control (QC) applications for Abbreviated New Drug Applications (ANDA) and commercial production of Cortexolone.

Page Keywords: Buy Cortexolone 17-Acetate | Purchase Cortexolone 17-Acetate | Cortexolone 17-Acetate suppliers | Cortexolone 17-Acetate manufacturers | Cortexolone 17-Acetate price | Cortexolone 17-Acetate Importer | Cortexolone 17-Acetate Exporter

Enquiry Now

Personal Details

Product Details

Related Products

CAT No: CL-CTXL-05
CAS No: 2767265-35-8
Mol Wt: 444.6
Mol F: C26H36O6
Inv. Status: Custom Synthesis
CAT No: CL-CTXL-01
CAS No: 152-58-9
Mol Wt: 346.5
Mol F: C21H30O4
Inv. Status: Custom Synthesis
CAT No: CL-CTXL-06
CAS No: 19608-30-1
Mol Wt: 458.6
Mol F: C27H38O6
Inv. Status: Custom Synthesis
CAT No: CL-CTXL-07
CAS No: NA
Mol Wt: 421
Mol F: C24H33ClO4
Inv. Status: Custom Synthesis
CAT No: CL-CTXL-02
CAS No: 853-27-0
Mol Wt: 328.5
Mol F: C21H28O3
Inv. Status: Custom Synthesis
CAT No: CL-CTXL-03
CAS No: 640-87-9
Mol Wt: 388.5
Mol F: C23H32O5
Inv. Status: Custom Synthesis
CAT No: CL-CTXL-04
CAS No: 95624-09-2
Mol Wt: 402.5
Mol F: C24H34O5
Inv. Status: Custom Synthesis
Subscribe for news letter:
  

© Cleanchem Laboratories LLP. All Rights Reserved.